Future Directions in Graft vs Host Disease Management
Closing out their panel on GVHD management, expert hematologist/oncologists share their hope for future evolution in the treatment landscape.
Treatment Armamentarium for Chronic Graft vs Host Disease
Comprehensive discussion on the pharmacologic treatment armamentarium available for patients with chronic graft vs host disease.
Optimal Staging Strategies for Chronic Graft vs Host Disease
Expert hematologist/oncologists highlight challenges in staging chronic graft vs host disease and share strategies to optimize cGHVD assessment.
Scenario 2: A 59-Year-Old Woman With Chronic GVHD
After reviewing a clinical scenario of chronic graft vs host disease, panelists consider the importance of different allogeneic transplant types.
Selecting Therapy for Patients With a Partial Response to Frontline Therapy
Shared insight on treatment approaches toward patients with acute graft vs host disease who experience partial response to frontline therapy.
Selecting Optimal Therapy for Acute GVHD
Focusing on pharmacologic options, expert panelists review frontline treatment strategies for patients with acute graft vs host disease.
Biomarkers for the Prognostication of Graft vs Host Disease
Expert hematologist/oncologists share their perspectives on use of biomarkers to help prognosticate graft vs host disease.
Scenario 1: A 44-Year-Old Man With Acute Graft vs Host Disease
Centering discussion on a scenario of acute graft vs host disease, expert panelists consider optimal workup of a patient showing signs of GVHD.
Understanding the Pathophysiology of Acute vs Chronic GVHD
Shared insight on the pathophysiology of graft vs host disease, with specific regard for differences between acute GVHD vs chronic GVHD.
Armamentarium for Graft vs Host Disease Prophylaxis
Hematologist/oncologists provide a broad overview of the pharmacologic agents used to prevent graft vs host disease at their institutions.
GVHD in the Context of Stem Cell or Allogeneic Transplant
Expert panelists elucidate the occurrence of graft vs host disease in patients receiving either stem cell or allogeneic transplantation.
2 Commerce Drive Cranbury, NJ 08512